Selective Laser Trabeculoplasty (SLT) represents a significant advancement in the management of open-angle glaucoma, offering a targeted approach to intraocular pressure (IIOP) control. This minimally invasive procedure utilizes low-energy, high-frequency laser pulses applied to the trabecular meshwork, the eye’s natural drainage system. By stimulating biological changes within the meshwork cells, SLT enhances outflow facility, thereby reducing IOP without the need for incisions or systemic medications.
Understanding the Mechanism of Action
The primary goal of SLT is to improve the drainage of aqueous humor, the fluid produced within the eye, to lower intraocular pressure. The laser energy is absorbed by melanin granules present in the trabecular meshwork cells. This selective absorption triggers a series of biochemical events, including the recruitment of macrophages, which clean the drainage pathways and improve outflow. Unlike older methods, SLT is considered a "cold" laser procedure, as it produces minimal thermal damage, preserving the structural integrity of the surrounding tissue.
Clinical Indications and Patient Selection
SLT is primarily indicated for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). It serves as an initial treatment option for those seeking to reduce reliance on topical medications or as an adjunct therapy when medications alone are insufficient. Ideal candidates typically have well-defined, open angles on gonioscopy and intraocular pressure in the mid-to-high range. The procedure is generally avoided in cases of angle-closure glaucoma or significant angle pigmentation, where alternative interventions are more appropriate.
Efficacy and Duration of Effect
Clinical studies consistently demonstrate that SLT can reduce intraocular pressure by 20-30% in a majority of treated eyes. The effect is often noticeable within one to two weeks, with peak pressure reduction occurring around one month post-treatment. While the results are long-lasting, the effect is not always permanent; many patients may require retreatment after several years. Factors influencing the longevity of the effect include the initial pressure level, the patient’s age, and the specific characteristics of the trabecular meshwork.
Advantages Over Alternative Treatments
Compared to incisional glaucoma surgeries, SLT offers a favorable risk profile with minimal side effects and downtime. Unlike topical prostaglandin analogs, which can cause ocular surface irritation and pigmentation changes, SLT provides a systemic reduction in pressure without daily eye drops. This is particularly beneficial for patients who struggle with the cost, adherence, or side effects associated with medical therapy. Furthermore, SLT can be safely repeated if necessary, making it a versatile tool in the glaucoma specialist’s arsenal.
Potential Risks and Considerations
Although complications are rare, patients should be informed of potential risks. These can include a transient spike in intraocular pressure immediately following the procedure, mild discomfort, or inflammation. In very rare instances, the elevated pressure may require management with medications or additional intervention. The procedure is contraindicated in eyes with a history of uveitis or those with extensive peripheral anterior synechiae, as the laser may be ineffective or could exacerbate existing inflammation.
The Procedure and Recovery Process
SLT is typically performed in an outpatient clinic setting using a slit-lamp biomicroscope. The procedure lasts approximately 15 to 20 minutes, during which the patient sits at the slit lamp and looks into a lens. Anesthetic eye drops are applied to ensure comfort, and a special contact lens is used to deliver the laser energy directly to the trabecular meshwork. Most patients resume normal activities the following day, although they are advised to use any prescribed anti-inflammatory eye drops for a short period to manage any transient inflammation.
